Search

for
Search:

Sort by

Research

450-480 / 1000+ results

research Docking-based workflow and ADME prediction of some compounds in Curcuma longa and Andrographis paniculata as polymerase PA-PB1 inhibitors of influenza A/H5N1 virus

8 citations , January 2023 in “Journal of Research in Pharmacy”

Compounds from turmeric and bitter show strong potential as antiviral agents against the influenza A virus.

research Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects

508 citations , June 2009 in “Current drug metabolism”

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

research 3,3-Diphenylpentane skeleton as a steroid skeleton substitute: Novel inhibitors of human 5α-reductase 1

13 citations , August 2007 in “Bioorganic & medicinal chemistry letters”

A new compound effectively inhibits human 5α-reductase 1.

research Tyrosine kinase inhibition and grey hair

59 citations , March 2003 in “The Lancet”

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

research Integrin-linked kinase inhibition via QLT0267 stops the epithelial outgrowth.

December 2015 in “OPAL (Open@LaTrobe) (La Trobe University)”

QLT0267 stops hair follicle cell growth and movement.

research 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo

September 2025 in “Journal of the American Academy of Dermatology”

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia

research Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia

April 2025 in “JAAD Case Reports”

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

research JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata

May 2023

research Alopecia Universalis: Never Give Up?

February 2025 in “PubMed”

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

research The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1

71 citations , May 2024 in “New England Journal of Medicine”

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

research Original synthetic monophenolic antioxidant with combined effect inhibits tumor growth in vivo

2 citations , January 2025 in “Сибирский научный медицинский журнал”

TS-13 effectively stops tumor growth and reduces chemotherapy side effects.

research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men

7 citations , August 1996 in “The Journal of Clinical Endocrinology and Metabolism”

research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis

41 citations , December 2015 in “JAMA Dermatology”

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

research Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study

August 2025 in “Journal of the American Academy of Dermatology”

research Linc-PINT downregulation of TGF-β signaling pathway in heart arrhythmia: an in silico analysis

April 2025 in “Journal of Diabetes & Metabolic Disorders”

Monitoring TGF-β and linc-PINT expression may help identify and treat high-risk heart arrhythmia patients.

research The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles.

3 citations , December 2000 in “PubMed”

CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.

research Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature

16 citations , August 2023 in “JAAD Case Reports”

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

research Discovery and Optimization of Novel Pyridines as Highly Potent and Selective Glycogen Synthase Kinase 3 Inhibitors

October 2019

New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.

research Ruxolitinib for the treatment of severe alopecia areata

37 citations , September 2018 in “Journal of the American Academy of Dermatology”

Ruxolitinib can help regrow hair in severe alopecia areata.

research Treatment of insulin resistance with tirzepatide leading to improvement of hair loss

12 citations , June 2024 in “JAAD Case Reports”

Tirzepatide may improve hair loss by reducing insulin resistance.

Observational Real-World Evidence on the Efficacy and Safety of Janus Kinase Inhibitors in the Treatment of Moderate to Severe Active Ulcerative Colitis

research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)

January 2024 in “Journal of Crohn's and colitis”

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

research Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata

4 citations , February 2024 in “Anais Brasileiros de Dermatologia”

research An urticarial drug eruption caused by tofacitinib for alopecia universalis

2 citations , April 2019 in “Dermatologic Therapy”

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

research America - A Diversity of Life Styles.

January 1975 in “NJEA Review”

The drug showed promise in treating renal cell carcinoma with manageable side effects.

TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris

research TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris

March 2026

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

research Unexpected Effect of Baricitinib Use: Observation of a Case of Hypertrichosis

March 2026 in “Indian Journal of Dermatology”

Baricitinib can cause excessive hair growth.

research Growth inhibition of mouse skin tumor by serine protease inhibitor ONO-3403.

1 citations , September 2001 in “PubMed”

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

research Synthesis and biological activity evaluation of new isatin-gallate hybrids as antioxidant and anticancer agents (in vitro) and in silico study as anticancer agents and coronavirus inhibitors

3 citations , June 2024 in “Pharmacia”

New isatin-gallate hybrids show promise as antioxidants, cancer treatments, and coronavirus inhibitors.

research Case Report: PTCH1 splice-site mutation and sonidegib treatment in Gorlin-Goltz syndrome: clinical insights from a family case study

February 2026 in “Frontiers in Medicine”

Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.

research Erlotinib-Induced Skin Inflammation Is IL-1 Mediated in KC-Tie2 Mice and Human Skin Organ Culture

15 citations , October 2014 in “The journal of investigative dermatology/Journal of investigative dermatology”

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

← Previous page Next page →